IP Library Patent Application 18193837
Patent Application
App. No. 18/193,837

Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And Ion Channel Inhibitors

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/193,837
Abstract

Disclosed are methods of treating a subject having cancer comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering an ion channel inhibitor to the subject. Disclosed are methods of killing a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength, and contacting the cancer cell with an ion channel inhibitor, wherein cancer cells are killed. Disclosed are methods of reducing cancer cell proliferation comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength, and contacting the cancer cell with an ion channel inhibitor, wherein the alternating electric fields and ion channel inhibitor provide an anti-proliferative effect of the cancer cell. Disclosed are methods of increasing survival rate of a subject having cancer comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering an ion channel inhibitor to the subject, wherein the subject has an increased survival rate.

Claims (34)

1 . A method of treating a subject having cancer comprising:

a) applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength,

wherein the target site comprises one or more cancer cells, and

b) administering a chloride ion channel inhibitor to the subject.

2 . The method of claim 1 , wherein the chloride ion channel inhibitor is a chloride intracellular channel (CLIC) inhibitor.

3 . The method of claim 2 , wherein the CLIC inhibitor is a CLIC1 or CLIC4 inhibitor.

4 . (canceled)

5 . The method of claim 2 , wherein the CLIC inhibitor is IAA94

6 . The method of claim 2 , wherein the CLIC inhibitor is a siRNA.

7 . The method of claim 6 , wherein the siRNA inhibits the expression of a protein selected from the group consisting of CLIC1, CLIC4, CLIC2, CLIC3, CLIC5, and CLIC6.

8 . (canceled)

9 . The method of claim 1 , wherein the alternating electric fields and chloride ion channel inhibitor reduces proliferation of the one or more cancer cells.

10 . The method of claim 1 , wherein the cancer is glioblastoma.

11 . The method of claim 1 , wherein the chloride ion channel inhibitor is administered prior to applying the alternating electric fields.

12 . The method of claim 1 , wherein the chloride ion channel inhibitor is administered after applying the alternating electric fields or simultaneously with applying the alternating electric fields.

13 . (canceled)

14 . A method of killing a cancer cell or reducing cancer cell proliferation comprising:

a) exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength, and

b) contacting the cancer cell with a chloride ion channel inhibitor.

15 . The method of claim 14 , wherein the chloride ion channel inhibitor is a chloride intracellular channel (CLIC) inhibitor

16 . The method of claim 15 , wherein the CLIC inhibitor is a CLIC1 or CLIC4 inhibitor.

17 . (canceled)

18 . The method of claim 14 , wherein the CLIC inhibitor is IAA94 or is siRNA.

19 . (canceled)

20 . The method of claim 18 , wherein the siRNA inhibits the expression of a protein selected from the group consisting of CLIC1, CLIC4, CLIC2, CLIC3, CLIC5, and CLIC6.

21 . (canceled)

22 . (canceled)

23 . (canceled)

24 . The method of claim 14 , wherein the cancer cell is in a subject.

25 .- 46 . (canceled)

47 . The method of claim 1 , wherein the frequency of the alternating electric fields is between 50 kHz and 1 MHz.

48 . The method of claim 47 , wherein the frequency of the alternating electric fields is 200 kHz.

49 . The method of claim 1 , wherein the field strength is between 0.5V/cm and 4V/cm.

50 . The method of claim 49 , wherein the field strength is 1V/cm.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2025
From: SMITH, STUART
To: NOVOCURE GMBH
Reel/Frame 071673/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2025
From: MAZZANTI, MICHELE
To: UNIVERSITY OF MILANO, DEPARTMENT OF BIOSCIENCE
Reel/Frame 071634/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2025
From: UNIVERSITY OF MILANO, DEPARTMENT OF BIOSCIENCE
To: NOVOCURE GMBH
Reel/Frame 071634/0302 →
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →